nonprofit logo

International Aids Vaccine Initiative Inc

Iavi

Learn about this cause: What are the reviews? Is it Legit? Do I like the mission? What is the CEO's salary?

EIN: 133870223 ✦ New york, NY ✦ Designated as a 501(c)(3)

Shop smarter and support your favorite cause at the same time! With the Give Freely browser extension, you'll automatically save money with coupons, and partner stores will donate to your chosen charity - at no extra cost to you. Start giving back with a single click. It's safe, free, and spam-free, guaranteed!

Overview

What is International Aids Vaccine Initiative Inc?

International Aids Vaccine Initiative Inc is a nonprofit scientific research organization based in New York, dedicated to developing vaccines and antibodies, primarily for HIV and other infectious diseases, in Africa, India, Europe, and the U.S. Their mission involves fostering collaborations among various sectors to explore innovative approaches to public health threats that disproportionately affect people living in poverty. Through rigorous clinical evaluations, IAVI advances vaccine and antibody candidates to establish their safety and efficacy, strengthening healthcare infrastructure and scientific capacity in partner countries. To date, they have conducted over 50 epidemiological studies, providing voluntary HIV testing, counseling services, and healthcare referrals to hundreds of thousands of individuals in Africa. IAVI's research is conducted with the highest scientific and ethical standards, and they have launched research consortia to address major scientific problems in biomedical product development. A significant portion of their work is conducted in developing countries where the need for infectious disease prevention is greatest.


Official website here: www.iavi.org

What are the reviews and ratings of this charity?

Charity Navigator Rating: 91% (Four-Star out of Four Stars)

The International Aids Vaccine Initiative Inc (IAVI) holds a strong rating of 91%, indicating a high level of transparency and effectiveness in its operations. With an impressive Accountability & Finance score of 94, the organization demonstrates responsible financial management and allocates a significant portion of its budget toward program expenses, achieving a program expense ratio of 87.68%.

However, user feedback reveals some concerns regarding its spending practices. A review from a member of the public criticized the organization for high expenses related to travel and accommodations, suggesting a potential misalignment with its mission priorities. Despite this, the organization's strong Leadership & Adaptability score of 100 reflects its capability to navigate challenges effectively and maintain a robust research agenda to combat infectious diseases.


This AI summary has been generated from information found on Charity Navigator and Great Nonprofits.

Is International Aids Vaccine Initiative Inc legitimate?

International Aids Vaccine Initiative Inc is a legitimate nonprofit organization registered as a 501(c)(3) entity. International Aids Vaccine Initiative Inc submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.


Heare are some key statistics you may want to consider:

Executive Compensation: $2,614,665
Professional Fundraising Fees: $0
Other Salaries and Wages: $33,612,789

For more financial information, click here


Official website here: www.iavi.org

What is the mission statement of International Aids Vaccine Initiative Inc?

The International Aids Vaccine Initiative Inc is a nonprofit scientific research organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases. Through research and clinical trials in Africa, India, Europe, and the US, the organization advances scientific discoveries and seeks to accelerate the introduction of affordable, globally accessible public health solutions in low-income countries. IAVI fosters unique collaborations among academia, industry, local communities, governments, and funders to explore new ways to address public health threats that disproportionately affect people living in poverty. The organization puts vaccine and antibody candidates through rigorous clinical evaluation to establish their safety and efficacy, strengthening healthcare infrastructure and scientific capacity in partner countries. To date, IAVI and its partners have advanced dozens of HIV vaccine candidates into early stage clinical trials and conducted more than 50 epidemiological studies, providing voluntary HIV testing, counseling services, and healthcare referrals to over 870,000 individuals in Africa. IAVI supports preclinical development and clinical testing of vaccine candidates and antibodies for various diseases, including tuberculosis, Lassa fever, Marburg, Ebola Sudan, and COVID-19.


Official website here: www.iavi.org

Who is the CEO of International Aids Vaccine Initiative Inc?

Mark B Feinberg is the President/Ceo of International Aids Vaccine Initiative Inc. The CEO's salary of International Aids Vaccine Initiative Inc is $666,687 and their total compensation is $763,253.


Official website here: www.iavi.org

What is the revenue of International Aids Vaccine Initiative Inc?

International Aids Vaccine Initiative Inc's revenue in 2022 was $146,782,280.


Official website here: www.iavi.org

Who are the executives of International Aids Vaccine Initiative Inc and what are their salaries?

The average compensation at International Aids Vaccine Initiative Inc during 2022 was $147,867. There are 245 employees and 14 volunteers at International Aids Vaccine Initiative Inc.


Here are 24 key members and their salaries (International Aids Vaccine Initiative Inc's CEO's salary is $666,687 and their total compensation is $763,253):


Mark B Feinberg (President/Ceo)
  • Compensation: $666,687
  • Related: $0
  • Other: $96,566
Eric Paul Goosby (Board Chair)
  • Compensation: $0
  • Related: $0
  • Other: $0
Robert Goldberg (Board Treasurer)
  • Compensation: $0
  • Related: $0
  • Other: $0
Linda-Gail Becker (Board Member)
  • Compensation: $0
  • Related: $0
  • Other: $0
David Blumberg (Board Member)
  • Compensation: $0
  • Related: $0
  • Other: $0
Jim Connolly (Board Member)
  • Compensation: $0
  • Related: $0
  • Other: $0
Mark Dybul (Board Member)
  • Compensation: $0
  • Related: $0
  • Other: $0
Wafaa El-Sadr (Board Member)
  • Compensation: $0
  • Related: $0
  • Other: $0
John Nkengasong (Board Member (Until 5/16/22))
  • Compensation: $0
  • Related: $0
  • Other: $0
Alexis M Pinto (Board Member)
  • Compensation: $0
  • Related: $0
  • Other: $0
John W Shiver (Board Member)
  • Compensation: $0
  • Related: $0
  • Other: $0
Susan Silbermann (Board Member)
  • Compensation: $0
  • Related: $0
  • Other: $0
Anne Martin Simonds (Board Member)
  • Compensation: $0
  • Related: $0
  • Other: $0
Rajeev Venkayya (Board Member)
  • Compensation: $0
  • Related: $0
  • Other: $0
Marijke Wijnroks (Board Member)
  • Compensation: $0
  • Related: $0
  • Other: $0
Ana Cespedes Montoya (Chief Operating Officer)
  • Compensation: $510,065
  • Related: $0
  • Other: $109,309
Louis D Schwartz (Asst. Sec. & Chief Financial Officer)
  • Compensation: $363,556
  • Related: $0
  • Other: $85,739
Min Ding (Gen. Couns. & Sec. (From 3/14/22))
  • Compensation: $325,059
  • Related: $0
  • Other: $67,838
Frances Sinha (Cpo, Vp Of Hr (Until 12/1/22))
  • Compensation: $345,114
  • Related: $0
  • Other: $44,733
Swati Gupta (Vp, Head Of Eid & Epidemiology)
  • Compensation: $364,496
  • Related: $0
  • Other: $86,183
Thomas Hassell (Vp, Pdc (Until 9/30/22))
  • Compensation: $353,175
  • Related: $0
  • Other: $75,197
Dagna Laufer (Vp & Head Of Clinical Development)
  • Compensation: $377,615
  • Related: $0
  • Other: $43,357
Christopher Parks - Assoc (Vp, Viral Vaccines & Head Of The Ddl)
  • Compensation: $340,566
  • Related: $0
  • Other: $70,686
Eric Skjeveland (Vp, Business Development)
  • Compensation: $314,481
  • Related: $0
  • Other: $17,149


Official website here: www.iavi.org

Where can I find the form 990 for International Aids Vaccine Initiative Inc?

International Aids Vaccine Initiative Inc's most recent form 990 was submitted in 2022 and can be accessed here.


Official website here: www.iavi.org

Learn more at the official website: www.iavi.org

Mission Statement of International Aids Vaccine Initiative Inc

International Aids Vaccine Initiative Inc, a nonprofit scientific research organization, is dedicated to translating scientific discoveries into affordable and globally accessible public health solutions. Their mission is to develop vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases.

IAVI conducts scientific and clinical research in Africa, India, Europe, and the United States to advance vaccine and antibody candidates for the developing world. By fostering unique collaborations among academia, industry, local communities, governments, and funders, IAVI explores new ways to tackle public health threats that disproportionately affect people living in poverty.

IAVI's rigorous process of clinical evaluation among key populations establishes the safety and efficacy of their candidates, strengthening the healthcare infrastructure and scientific capacity of countries where they operate. To date, IAVI and its partners have advanced dozens of HIV vaccine candidates into early stage clinical trials, with one recently yielding promising results. IAVI has also conducted more than 50 epidemiological studies and provided voluntary HIV testing, counseling services, and healthcare referrals to over 870,000 individuals in Africa.

Beyond HIV, IAVI supports preclinical development and clinical testing of vaccine candidates for other diseases, including tuberculosis, Lassa fever, Marburg, Ebola Sudan, and COVID-19, as well as antibody candidates for disease prevention and treatment. IAVI's trials adhere to the highest scientific and ethical standards to protect the rights, well-being, and dignity of trial volunteers. IAVI has also launched research consortia to address major scientific problems of biomedical product development. A significant portion of the research IAVI supports is conducted in developing countries where the need for infectious disease prevention is greatest. IAVI also supports external researchers by providing technical and scientific expertise to accelerate the development of their own products.

Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!

Impact




October, 2024

International Aids Vaccine Initiative Inc (IAVI) plays a critical role in addressing global public health challenges, particularly in the field of infectious diseases like HIV, tuberculosis, and emerging pathogens. Through its extensive research and development efforts, IAVI translates scientific discoveries into affordable and accessible healthcare solutions for marginalized populations.

Conducting scientific and clinical research across various regions, including Africa, India, Europe, and the U.S., IAVI focuses on developing vaccines and antibodies specifically tailored for the developing world. This includes advancing numerous HIV vaccine candidates through rigorous clinical evaluation, marked by significant milestones such as the first HIV vaccine trials in sub-Saharan Africa and pioneering the first mRNA HIV vaccine candidate trial on the continent.

IAVI's impact extends beyond just vaccine development. The organization enhances healthcare infrastructure and scientific capacity in regions where it operates, having conducted over 50 epidemiological studies and provided vital health services to more than 870,000 individuals. Their commitment to ethical research standards ensures the dignity, rights, and well-being of trial participants are safeguarded throughout the process.

Additionally, IAVI's collaborative approach fosters partnerships among academia, industry, local communities, and governments, contributing to more effective solutions to public health crises affecting low-income populations. By supporting preclinical development and clinical testing for a range of diseases, including TB and Ebola, IAVI not only addresses immediate health threats but also strengthens the global fight against infectious diseases.

Ultimately, IAVI's multifaceted impact is evident in its significant contributions to vaccine research and development, its community health initiatives, and its role in enhancing scientific collaboration, making it a key player in the pursuit of global health equity.




This information is meant to be a general summary of International Aids Vaccine Initiative Inc. Please take the time to review official sources before making any decisions based upon the content provided here.


Financials

This financial information is from Propublica.

Revenue
$146,782,280 (2022)
Expenses
$131,188,762 (2022)
Efficiency

Other financial information:

This information is from the most recently submitted tax form from this organization, which was in 2022.

  • Investment Income: -$178,814
  • Program Service Revenue: $2,569,928
  • Gross Receipts: $164,971,598

Assets and Liabilities:

  • Total Assets: $128,948,484
  • Total Liabilities: $62,681,430
  • Net Assets: $66,267,054

Want to help this charity, for free? You can click here to learn more about Give Freely

Programs

Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.

CONTRACT SERVICE FEES

Revenue

$2,569,928

Organization Details

Founding Year

1996

Principal Officer

Mark B Feinberg

Main Address

125 BROAD STREET 9TH FL, NEW YORK, NY, 10004

NTEE Category

Code: Q300 - International

If you are a representative of International Aids Vaccine Initiative Inc and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.